Previous close | 62.28 |
Open | 62.14 |
Bid | 60.72 x 50000 |
Ask | 60.76 x 50000 |
Day's range | 61.00 - 62.68 |
52-week range | 61.00 - 80.08 |
Volume | |
Avg. volume | 498 |
Market cap | 76.548B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 14.52 |
EPS (TTM) | 4.20 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.85 (4.57%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.
After a sell off that saw its shares fall nearly 20% this year, the biotech Gilead Sciences turned in first-quarter results on Thursday that were slightly better than anticipated. Sales for the quarter were $6.7 billion, beating the analyst consensus estimate as calculated by FactSet which was $6.4 billion. The company reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.